ARTICLE | Editor’s Commentary
Some firms are no longer making their latest funds their largest; others may follow
By Paul Bonanos, Director of Biopharma Intelligence
December 13, 2024 9:39 PM UTC
Until a couple of years ago, nearly every new biotech venture fund I’d written about was the largest yet for the firm that raised it. But lately, it appears some biotech VCs have hit a ceiling, capping their new funds at or below the amount of their previous vehicles.
Three years into a tough slog for biotechs, some firms are resetting expectations. It isn’t clear which changes in the life sciences marketplace will be permanent and which are merely cyclical, but some VCs’ fundraising clearly reflects their adjustments…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654457/vc-fundraising-in-a-post-supercycle-era-a-perspective